Jim Cramer Notes Pfizer (PFE) Has “Got a Lot of Stuff in the Pipeline”

Group 1 - Pfizer Inc. is currently priced at $26 with a yield of 6.4% and has a significant pipeline of products [1] - The company is a principal vaccine provider in the U.S., but the vaccine business is facing challenges, particularly in light of public scrutiny [3] - There are concerns regarding the effectiveness and public perception of Pfizer's vaccines, especially in relation to criticisms from figures like RFK Jr. [3] Group 2 - While Pfizer is recognized as a potential investment, certain AI stocks are perceived to offer greater upside potential and lower downside risk [4]